文献速递血脂与心血管预防

LILRB5错义变异与他汀不耐受及肌痛相关

A common missense variant of LILRB5 is associated with statin intolerance and myalgia.
PubMed 文献 · Eur Heart J · 2017-01-01

在GoDARTS队列中,LILRB5 Asp247Gly变异与两种他汀不耐受表型相关,并在PREDICTION-ADR联盟和JUPITER试验中重复验证。荟萃分析显示该变异与他汀不耐受相关结局呈一致关联,提示免疫遗传因素参与他汀肌痛发生。

要点

  • LILRB5 Asp247Gly变异与他汀不耐受风险升高相关,纯合子风险更高。
  • 该关联在不依赖CK升高的不耐受定义及肌痛结局中均被重复验证。
  • 真性他汀诱导肌痛与非特异性肌痛可能为不同机制,免疫系统或参与其中。

核心结论

  • LILRB5 Asp247Gly是与他汀不耐受相关的新型免疫遗传因素,携带该变异者更可能对他汀不耐受。

研究设计与样本

  • 在GoDARTS队列中检验LILRB5 Asp247Gly与他汀不耐受的关联,并在PREDICTION-ADR联盟他汀诱导肌病病例及JUPITER瑞舒伐他汀随机临床试验中重复验证,最后进行荟萃分析。

主要发现

  • GoDARTS中,Asp247变异与「CK升高且不依从治疗」定义的他汀不耐受相关(OR 1.81;95%CI:1.34-2.45),也与「在换用两种及以上其他他汀前对最低批准剂量不耐受」相关(OR 1.36;95%CI:1.07-1.73)。
  • Asp247纯合子发生上述两种不耐受定义的风险均增加,且第二种定义不依赖CK升高。
  • PREDICTION-ADR联盟他汀诱导肌病病例中重复验证(OR 1.48;95%CI:1.05-2.10),JUPITER试验中瑞舒伐他汀相关肌痛亦重复验证(OR 1.35;95%CI:1.10-1.68)。
  • 跨研究荟萃分析显示Asp247Gly与他汀不耐受相关结局呈一致关联(OR 1.34;95%CI:1.16-1.54)。

临床怎么用

  • 对于反复出现他汀不耐受或肌痛的患者,可考虑LILRB5 Asp247Gly变异作为免疫遗传易感标志的线索。
  • 评估他汀不耐受时,不依赖CK升高的不耐受表型同样具有临床意义。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: A genetic variant in LILRB5 (leukocyte immunoglobulin-like receptor subfamily-B) (rs12975366: T > C: Asp247Gly) has been reported to be associated with lower creatine phosphokinase (CK) and lactate dehydrogenase (LDH) levels. Both biomarkers are released from injured muscle tissue, making this variant a potential candidate for susceptibility to muscle-related symptoms. We examined the association of this variant with statin intolerance ascertained from electronic medical records in the GoDARTS study. METHODS AND RESULTS: In the GoDARTS cohort, the LILRB5 Asp247 variant was associated with statin intolerance (SI) phenotypes; one defined as having raised CK and being non-adherent to therapy [odds ratio (OR) 1.81; 95% confidence interval (CI): 1.34-2.45] and the other as being intolerant to the lowest approved dose of a statin before being switched to two or more other statins (OR 1.36; 95% CI: 1.07-1.73). Those homozygous for Asp247 had increased odds of developing both definitions of intolerance. Importantly the second definition did not rely on CK elevations. These results were replicated in adjudicated cases of statin-induced myopathy in the PREDICTION-ADR consortium (OR1.48; 95% CI: 1.05-2.10) and for the development of myalgia in the JUPITER randomized clinical trial of rosuvastatin (OR1.35, 95% CI: 1.10-1.68). A meta-analysis across the studies showed a consistent association between Asp247Gly and outcomes associated with SI (OR1.34; 95% CI: 1.16-1.54). CONCLUSION: This study presents a novel immunogenetic factor associated with statin intolerance, an important risk factor for cardiovascular outcomes. The results suggest that true statin-induced myalgia and non-specific myalgia are distinct, with a potential role for the immune system in their development. We identify a genetic group that is more likely to be intolerant to their statins.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. K Siddiqui M, Maroteau C, Veluchamy A, et al. A common missense variant of LILRB5 is associated with statin intolerance and myalgia. Eur Heart J. 2017. PMID: 29020356. doi:10.1093/eurheartj/ehx467

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。